Bayer Not Restructuring Amidst Litigation Threat

• Bayer faces roughly 100,000 Roundup-related lawsuits from plaintiffs alleging the company failed to warn about glyphosate's potential to cause cancer, stemming from its $63 billion Monsanto acquisition in 2018
• The company has proposed a $7.25 billion settlement to resolve most pending cases, though some plaintiffs are objecting to the terms
• Legislative efforts to gain legal immunity have largely failed, with the House stripping pesticide liability protections from the Farm Bill in April; only North Dakota, Kentucky, and Georgia have passed favorable legislation

Bayer Maintains Current Structure Despite Roundup Litigation Crisis

Key Developments:

Bayer confirmed Tuesday it has no plans to spin off Monsanto despite facing approximately 100,000 lawsuits related to its Roundup weedkiller. CEO Bill Anderson warned that continued litigation threatens U.S. glyphosate production, stating: "If there's not a solution to the litigation problem on glyphosate, there won't be American-produced glyphosate." Bayer is currently the only U.S. producer, though farmers also import generic versions from China.

Background:

Bayer acquired Monsanto for $63 billion in 2018, inheriting litigation from consumers claiming the company failed to warn that Roundup's active ingredient, glyphosate, could cause cancer, specifically non-Hodgkin lymphoma.

Current Strategies:

The company is pursuing multiple approaches to address the legal crisis:

• Proposed $7.25 billion settlement to resolve most pending lawsuits, though some plaintiffs are objecting
• Supreme Court appeal of a $1.25 million Missouri jury verdict
• State-level legislative efforts to limit pesticide manufacturer liability

Legislative Efforts:

Bayer has supported bills in multiple states to prevent lawsuits against pesticide manufacturers over cancer warnings. Success has been limited to North Dakota, Kentucky, and Georgia. A significant setback occurred in April when the House passed a Farm Bill version removing provisions that would have shielded pesticide companies from certain lawsuits.

Market Implications:

While restructuring remains a "viable option," Bayer is currently focused on performance improvement and litigation management rather than corporate reorganization. The outcome of these legal battles could significantly impact U.S. glyphosate availability and the broader agricultural sector.